Eteplirsen: Phase III started

Sarepta began the open-label, U.S. Phase III PROMOVI trial to evaluate 30 mg/kg IV eteplirsen once weekly for 48 weeks in about 80 ambulatory patients ages 7-16 with genetic deletions amenable to exon...